GB Sciences GBLX · USD

Its shares trade under the ticker GBLX. It has been listed since 22 December 2003. In the fiscal year to 31 March 2021, it reported revenue of $3.1m and a net loss of $3.7m. At that date it held total assets of $10.8m and shareholders' equity of −$1.5m.

GB Sciences, Inc. engages in the biopharmaceutical research and development of cannabis plant into medicines, therapies, and treatments. The company is headquartered in Las Vegas, Nevada. The company went IPO on 2003-12-22. The company seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies and treatments for a range of ailments. The company intends to conduct its business operations, through its subsidiaries in approximately three operating units, which include Solutions, Sciences and Product divisions. The Solutions division involves the development and use of its suite of controlled-climate indoor agricultural technology growing and cultivation Suites, including TissueBLOX, GrowBLOX, CureBLOX and ExtractionLAB. The Science division is engaged in preclinical testing of its biopharmaceutical cannabinoid product prototypes to begin future human clinical trials.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Andrea Small-HowardChairman of the Board, Chief Executive Officer, Chief Financial Officer, Chief Scientific Officer, since 2014$138,000
• Mr. Zach SwartsChief Financial Officer, Treasurer$120,000
• Mr. Gary HenrieCompany Secretary

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.